Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07062549 · ClinicalTrials.gov registry record · Phase 1
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
A Phase 1 study of Renal Cell Carcinoma (Kidney Cancer), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT07062549 is a Phase 1 study of Renal Cell Carcinoma (Kidney Cancer) that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07062549, a Phase 1 study of Renal Cell Carcinoma (Kidney Cancer), is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan
Conditions Studied
Interventions
- DRUG 111In-XYIMSR-01
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-01-26 |
| Est. Completion | 2029-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07062549
The ClinicalTrials.gov registry entry for NCT07062549 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma (Kidney Cancer) appearing as the primary indexed condition, and to 1 intervention - of which 111In-XYIMSR-01 is the first listed.
NCT07062549 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT07062549 about?
NCT07062549 is a clinical study titled "Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell". This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan
What is the current status of trial NCT07062549?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-01-26. Estimated completion is 2029-07.
What conditions does trial NCT07062549 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma (Kidney Cancer).
What interventions are being tested in trial NCT07062549?
The interventions under investigation include: 111In-XYIMSR-01 (DRUG).
Who is sponsoring clinical trial NCT07062549?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07062549 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma (Kidney Cancer)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.